Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances
Altimmune, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $3.01
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS